Diet and diabetic retinopathy: Insights from the Diabetes Control and Complications Trial (DCCT)

MedGenMed Medscape General Medicine

Volumn 7, Issue 1, 2005, Pages

  Cundiff, David K ^a   Nigg, Claudio R ^b  

^a University of Hawaii at Manoa ^*

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; DIETARY INTAKE; DISEASE COURSE; DRUG UTILIZATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; LIFE STYLE; MALE; RANDOMIZED CONTROLLED TRIALS;

EID: 25144525610     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial. The Kroc Collaborative Study Group. N Engl J Med. 1984;311:365-372
2. Lauritzen T, Frost-Larsen K, Larsen HW, Keckert T, Group SS. Effect of one-year near normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet. 1983;1:200-204.
3. Hanssen KF, Dahl-Jorgensen K, Lauritzen T, Feldt-Rasmussen C. Diabetic control and microvascular complications: the near-normoglycaemic experience. Diabetologia. 1986;29:677-684.
4. Holman RR, Dorman TL, Mazon-White V, et al. Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients: a two-year randomized prospective study. Lancet. 1983;1:204-208.
5. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF. Effects of intensified insulin treatment on retinal vessels in diabetic patients. Br J Ophthalmol. 1988;72:666-673.
6. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF. The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy. Arch Ophthalmol (United States). 1988;106:1242-1246.
7. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res J). 1986;293:1195-1199.
8. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF. Oscillatory potentials, retinopathy, and long-term glucose control in insulin-dependent diabetes. Acta Ophthalmol Scand. 1992;70:705-712.
9. Hanssen KF, Bangstadm HJ, Brinchmann-Hansenm O, et al. Blood glucose control and diabetic microvascular complications: long-term effects of near-normoglycaemia. Diabet Med. 1992;9:697-705.
10. Brinchmann-Hansen O, Dahl-Jorgensen K, Sandvik L. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ. 1992;304:19-22.
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
12. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care. 1996;19:195-203.
13. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med. 1991;90:450-459.
14. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271-286.
15. Ford-Adams ME, Murphy NP, Moore EJ, et al. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med. 2003;20:656-660.
16. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. JAMA. 2003;289:2560-2572. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf Accessed December 23, 2004.
17. Kingsley LA, Dorman JS, Doft BH, et al. An epidemiologic approach to the study of retinopathy: the Pittsburgh diabetic morbidity and retinopathy studies. DiabetesRes Clin Pract. 1988;4:99-109.
18. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). National Cholesterol Education Program. May 2001. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/profmats.htm Accessed April 2, 2003.
19. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (American Diabetes Association). Diabetes Care. 2002;25:S50-S60.
20. US Department of Health and Human Services. The Surgeon General's call to action to prevent and decrease overweight and obesity. US Department of Health and Human Services, Public Health Service, Office of the Surgeon General. Available from: US GPO, Washington. 2001. Available at: http://www.surgeongeneral.gov/topics/obesity/ Accessed February 1, 2003.
21. Physical activity/exercise and diabetes. Diabetes Care. 2004;27:58S-62S.
22. Chaturvedi N, Stephenson JM, Fuller JH. The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care. 1995;18:785-792.
23. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care. 1999;22:1887-1898.
24. Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care. 1990;13:741-747.
25. The Diabetes Control and Complications Trial Research Group. DCCT Protocol. Springfield, Va: National Technical Information Service. US Dept of Commerce publication; 1988. PB 88-116462-AS.
26. The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes. 1986;35:530-545.
27. Implementation of a multicomponent process to obtain informed consent in the Diabetes Control and Complications Trial. Control Clin Trials. 1989;10:1-19.
28. The Diabetes Control and Complications Trial: results of the feasibility study. Diabetes Care. 1987;10:1-19.
29. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology. 1991;98(suppl):741-756.
30. The Diabetes Control and Complications Trial Research Group. Diabetes Control and Complications Trial Research Group: results of the feasibility study. Diabetes Care. 1987;10:1-19.
31. Assessment of hemoglobin A sub 1c in the Diabetes Control and Complications Trial (DCCT). Clin Chem. 1987;33:2267-2227.
32. Burke BS. Diet history as a tool in research. JAMA. 1947;23:1041-1046.
33. Schmidt LE, Cox MS, Buzzard IM, Cleary PA. Reproducibility of a comprehensive diet history in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc. 1994;94:1392-1397.
34. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care. 1988;11:567-573.
35. Bland JM, Altman DG. Statistics notes: multiple significance tests: the Bonferroni method. BMJ. 1995;310:170.
36. Cundiff DK. Diet and tobacco use: analysis of data from the Diabetic Control and Complications Trial, a randomized study. Medscape General Medicine. 2002;4(1). Available at: http://www.medscape.com/viewarticle/414943 Accessed December 23, 2004.
37. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.